Yes, it will evolve further, but human ACE2 receptors aren't evolving rapidly within a generation any time soon. There's a metaphorical window of possible mutations that will allow SARSCov2 to bind to receptors and a huge swath of that window clearly is taken up by protection from vaccines (especially mRNA ones). There is a finite space in which it could still evolve _and_ evade vaccines. That space is likely _extremely_ small. "Too much" evolution renders it ineffective at infecting humans.
mikepurvis|4 years ago
Indeed, Pfizer has announced that it is working on a booster that specifically targets Delta, so that says to me that there is very much still a concern here:
https://www.cnbc.com/2021/07/08/pfizer-says-it-is-developing...